Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Lowers 2014 Guidance, Cites Delay of Contracts


NEW YORK (Genomeweb News) – Proteome Sciences this week lowered its full year 2014 guidance, citing delays in the timing of several contracts.

The company said that as a result it expects 2014 revenues to be "somewhat lower" than the £2.14 million ($3.35 million) in revenues it posted in 2013.

The company said that it expected the delayed revenues to be captured in 2015, based on strong growth in its biomarker services and TMT reagent businesses.

Proteome Sciences added that it has begun discussions with several parties regarding outlicensing its biomarkers for detection of mild cognitive impairment and Alzheimer's disease.